Please assess the completion status of the following clinical trial:

Trial Title: Oxycodone DETERx™ Versus Placebo in Chronic Low Back Pain (CLBP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or non-pregnant female 18-75 years of age (inclusive) at the time of consent.~* Must have a clinical diagnosis of moderate-to-severe CLBP for a minimum of 6 months prior to screening.~* Must qualify for ATC opioid therapy for treatment of CLBP.~* Must be classified as non-malignant and non-neuropathic (Class 1 and 2), neuropathic (Class 3), or symptomatic for more than 6 months after low back pain surgery (Class 9) based on the Quebec Task Force Scale score.~* Female subjects of childbearing potential will use an acceptable method of birth control.~* Must be in general good health based on screening physical examination.~* Must be willing and able to comply with all study procedures and visit requirements.~Exclusion Criteria:~* Known to be refractory or intolerant to the analgesic effects of opioids or have failed previous opioid therapy.~* A medical condition that would compromise the subject's ability to swallow, absorb, metabolize, or excrete the study drug, including (but not limited to) intractable nausea and/or vomiting and/or severe gastrointestinal narrowing (pathologic or iatrogenic), bowel obstruction, ileostomy, colostomy, or is suspected of having paralytic ileus.~* A surgical procedure for back pain within 6 months prior to the Screening Visit.~* Any other chronic pain condition other than CLBP that would interfere with the assessment of CLBP (e.g., osteoarthritis, rheumatoid arthritis, post-herpetic neuralgia, pain associated with diabetic neuropathy, fibromyalgia, migraine headaches requiring opioid therapy).~* Known history of major depressive disorder that is not controlled with medication or has other conditions that produce significant cognitive or emotional disability.~* Any clinically significant unstable medical abnormality or acute or chronic disease of the cardiovascular, gastrointestinal, respiratory (e.g., chronic obstructive pulmonary disease), hepatic, or renal systems.~* Known history of alcohol and/or drug abuse.~* Positive urine drug screen for illegal or non-prescribed drugs~* Known history of seizure disorder, epilepsy, convulsions, or increased intracranial pressure anytime during the subject's life except pediatric febrile seizures.~* Known history of head injury within 6 months of Screening Visit.~* Current malignancy or a history within past 2 years of malignancy, with the exception of basal cell carcinoma or cervical carcinoma in situ that have been successfully treated.~* Positive for human immunodeficiency virus (HIV) or hepatitis B surface antigen, or hepatitis C antibody~* Subject is not able or is unwilling to meet the study attendance requirements.~Other protocol specific inclusion and exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Oxycodone DETERx (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete